Kadmon Investors and Media

Investors

Press Releases

Press Releases

Sanofi To Acquire Kadmon To Further Strengthen Growth of Transplant Business

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy PARIS, FRANCE and NEW YORK, NY / ACCESSWIRE / September 8, 2021 /... Read More

Kadmon Announces U.S. Availability of REZUROCK™ (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)

NEW YORK, NY / ACCESSWIRE / August 19, 2021   /   Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets is now commercially available for shipment to prescribed patients in the United States . REZUROCK was approved on July 16, 2021 by the... Read More

Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results

NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021. "The recent U.S. FDA approval of REZUROCK marked a transformative event for Kadmon and for patients living... Read More

Kadmon Announces REZUROCK™ (belumosudil) Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation

NEW YORK, NY / ACCESSWIRE / August 4, 2021 /   Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the National Comprehensive Cancer Network ® (NCCN) added REZUROCK TM (belumosudil) tablets to its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for Hematopoietic Cell... Read More

Kadmon Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK™ (Belumosudil) in Chronic Graft-Versus-Host Disease (cGVHD)

- REZUROCK is approved by the U.S. FDA for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - NEW YORK, NY / ACCESSWIRE / July 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that data from the... Read More

U.S. FDA Grants Full Approval of REZUROCK™ (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)

- REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - - Kadmon to Host Conference Call on Monday, July 19, 2021 at 8:00 a.m. ET - NEW YORK, NY / ACCESSWIRE / July 16, 2021   /   Kadmon... Read More

Kadmon to Present at Upcoming Investor Conferences

NEW YORK, NY / ACCESSWIRE / May 25, 2021   /   Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that Harlan W. Waksal , M.D., President and Chief Executive Officer, will present at the following virtual investor conferences: Jefferies Virtual Healthcare Conference Date: Tuesday, June 1, 2021... Read More

Kadmon to Present Initial Safety Data from Phase 1 Study of KD033 at the 2021 American Society of Clinical Oncology Annual Meeting

- Results Demonstrate KD033 was Well Tolerated in All Patients through Initial Dose Cohorts, Allowing for Continuation of Dose Escalation - NEW YORK, NY / ACCESSWIRE / May 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced initial safety data from the ongoing Phase 1 clinical trial of... Read More

Kadmon Provides Business Update and Reports First Quarter 2021 Financial Results

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021. "We continue to ramp up commercial launch preparation activities for belumosudil in anticipation of the PDUFA... Read More

Kadmon Announces Publication of Phase 2a Clinical Trial Results of Belumosudil for cGVHD in the Journal of Clinical Oncology

NEW YORK, NY / ACCESSWIRE / April 21, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil (KD025) for chronic graft-versus-host disease (cGVHD). The results were published in the Journal of Clinical... Read More
Displaying 1 - 10 of 20